Plasminogen activator Inhibitor-1 in systemic sclerosis: A nexus of fibrosis, vasculopathy, and senescence
Biomedical Journal · 2026
DOI: 10.1016/j.bj.2025.100906 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomedical Journal, 2026. Verfasst von Takuya Takahashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Plasminogen Activator Inhibitor 1, Fibrosis, Cellular Senescence. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Plasminogen activator inhibitor-1 (PAI-1), a key regulator of the fibrinolytic system, has emerged as a multifaceted contributor to the pathogenesis of systemic sclerosis (SSc). Beyond its classical role in inhibiting plasminogen activation, PAI-1 is implicated in the dysregulation of vascular remodeling, promotion of fibrosis, modulation of immune responses, and the maintenance of cellular senescence-all of which are hallmarks of SSc. Notably, elevated PAI-1 expression has been observed in both patient-derived tissues and experimental models of the disease. Mice deficient in the urokinase-type plasminogen activator receptor (uPAR), which functions with its ligand urokinase-type plasminogen activator (uPA) in the plasminogen activation system, exhibit impaired fibrinolysis and spontaneously develop vasculopathy and fibrosis, closely mirroring human SSc. These findings underscore the pathogenic relevance of the uPA-uPAR-PAI-1 axis in disease progression. Moreover, recent studies suggest that pharmacological inhibition of PAI-1 may not only ameliorate fibrosis and vascular abnormalities but also promote the clearance of senescent cells, thereby interrupting the vicious cycle of chronic inflammation and maladaptive tissue remodeling in SSc. This review highlights the emerging roles of PAI-1 in SSc pathophysiology and explores its potential as a novel therapeutic target for disease modification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: takehiro.takahashi@derma.med.tohoku.ac.jp.
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: yasano@derma.med.tohoku.ac.jp.
Zitieren
APA
Takahashi, T., Takahashi, T., & Asano, Y. (2026). Plasminogen activator Inhibitor-1 in systemic sclerosis: A nexus of fibrosis, vasculopathy, and senescence. Biomedical Journal. https://doi.org/10.1016/j.bj.2025.100906
Vancouver
Takahashi T, Takahashi T, Asano Y. Plasminogen activator Inhibitor-1 in systemic sclerosis: A nexus of fibrosis, vasculopathy, and senescence. Biomedical Journal. 2026. doi:10.1016/j.bj.2025.100906
BibTeX
@article{Takahashi2026,
author = {Takahashi, Takuya and Takahashi, Takehiro and Asano, Yoshihide},
title = {Plasminogen activator Inhibitor-1 in systemic sclerosis: A nexus of fibrosis, vasculopathy, and senescence},
journal = {Biomedical Journal},
year = {2026},
doi = {10.1016/j.bj.2025.100906}
}
EUVIMED